Showing results (261-270 of 332) with videos related to
Sort By:
Pageof 34
Autoimmunity Reviews|May 11, 2021
Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensusFerdinando D'Amico, Virginia Solitano, Daniel Aletaha, et al.Journal of Crohn'S & Colitis|March 1, 2018
Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical TrialEugeni Domènech, Julián Panés, Joaquín Hinojosa, et al.Inflammatory Bowel Diseases|November 20, 2009
Ulcerative colitis in northern Portugal and Galicia in SpainManuel Barreiro-de Acosta, Fernando Magro, Daniel Carpio, et al.The Lancet. Gastroenterology & Hepatology|February 5, 2022
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trialSilvio Danese, Severine Vermeire, Geert D'Haens, et al.Alimentary Pharmacology & Therapeutics|November 30, 2023
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUSTLaurent Peyrin-Biroulet, Séverine Vermeire, Geert D'Haens, et al.Clinical and Translational Gastroenterology|May 1, 2020
Genetic Variants of the MGAT5 Gene Are Functionally Implicated in the Modulation of T Cells Glycosylation and Plasma IgG Glycome Composition in Ulcerative ColitisMárcia S Pereira, Cecília Durães, Telmo A Catarino, et al.Journal of Crohn'S & Colitis|December 3, 2010
Clinical practice in Crohn's disease in bordering regions of two countries: different medical options, distinct surgical eventsFernando Magro, Manuel Barreiro-de Acosta, Paula Lago, et al.Journal of Crohn'S & Colitis|July 24, 2025
Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension StudyEdward V Loftus, Geert D'Haens, Edouard Louis, et al.Medrxiv : the Preprint Server for Health Sciences|February 27, 2026
Integrated metabolomics and genetic analyses reveal loss of protective docosahexaenoic acid as a key driver linking ultra-processed food to Crohn's disease riskSidan Wang, Lintao Dan, Xixian Ruan, et al.Alimentary Pharmacology & Therapeutics|April 2, 2019
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patientsLieven Pouillon, Silvio Danese, Ailsa Hart, et al.Pageof 34